JINDOYUAN PHARMACEUTICAL CO., LTD. ANNOUNCED IN ITS ANNUAL REPORT ON DECEMBER 31, 2023 THAT THE COMPANY'S NET LOSS FOR THE YEAR WAS APPROXIMATELY RMB1060.8 MILLION. The total assets of the company are RMB869.2 million and total liabilities are RMB411.1 million. The company had no revenue from product sales for the year, but received a total of RMB8.7 million in government subsidies to compensate for research and development expenses. PwC audited the company's financial statements and found no significant errors. Gold Dou Wan Pharmaceuticals has been listed on the main board of the Hong Kong Stock Exchange since 22 May 2020. The company's financial risk management includes market risk, credit risk and liquidity risk, with the exception of wealth management products and foreign currency options, with...Show More

JINDOYUAN PHARMACEUTICAL CO., LTD. ANNOUNCED IN ITS ANNUAL REPORT ON DECEMBER 31, 2023 THAT THE COMPANY'S NET LOSS FOR THE YEAR WAS APPROXIMATELY RMB1060.8 MILLION. The total assets of the company are RMB869.2 million and total liabilities are RMB411.1 million. The company had no revenue from product sales for the year, but received a total of RMB8.7 million in government subsidies to compensate for research and development expenses. PwC audited the company's financial statements and found no significant errors. Gold Dou Wan Pharmaceuticals has been listed on the main board of the Hong Kong Stock Exchange since 22 May 2020. The company's financial risk management includes market risk, credit risk and liquidity risk, with the exception of wealth management products and foreign currency options, with no significant financial assets or liabilities measured at fair value. Since most transactions are settled in RMB, the company has no significant foreign exchange risk. The Company monitors capital based on the Capital Structure Ratio. As cash and cash equivalents exceed total borrowings, this ratio is not applicable. The Company has not adopted any new guidelines and interpretations that have not been in effect since the fiscal year began on January 1, 2023. Key accounting estimates and determinations of the company include development expenses, depreciation testing of intangible assets that are not yet ready for use, inventory preparation, and the useful life of fixed assets. The Board of Directors is responsible for preparing consolidated financial statements in accordance with the disclosure requirements of the International Financial Reporting Standards and the Hong Kong Companies Ordinance.